glp-1 nz Calocurb, the New Zealand-based company bringing the world the first 100% natural activator, recently announced the publication of a new clinical study in US medical journal, Obesity Pillars, demonstrating Calocurb's effectiveness The Other Side of the

Is microdosing safe

Potential risks include inadequate disease management, unpredictable side effects and interactions with other medications. Dont be fooled by social media Its easy to get caught up in what youre seeing and hearing online, but if it seems too good to be true it probably is

People with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pancreatitis, or severe gastrointestinal conditions should avoid GLP1 weight-loss drugs unless specifically advised by their physician

The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis

Notably, about one in four of these patients did not carry a type 2 diabetes diagnosis , suggesting that a substantial portion of GLP-1 use is being driven by weight loss and other emerging indications outside of diabetes care (Figure 2)